文献速递免疫规划传染病防控与疫情报告妇幼与学校卫生

德国引入PCV13后肺炎链球菌血清型3相关肺炎旁胸腔积液/脓胸增加

Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany.
PubMed 文献 · Vaccine · 2019-11-14

德国全国儿童医院监测研究纳入2010年10月至2018年6月584例细菌学确诊的肺炎旁胸腔积液/脓胸患儿,其中256例检出肺炎链球菌,114例完成血清分型。2014年7月至2018年6月血清型3占比升至62.7%,血清型3病例年龄更小且更常入住ICU,并出现较多疫苗突破和疫苗失败病例;作者建议未来PCV应包含对血清型3更有效的成分。

要点

  • 584例患儿中256例(43.8%)检出肺炎链球菌,114例完成血清分型。
  • 2014年7月至2018年6月血清型3占62.7%,成为优势血清型。
  • 血清型3病例中位年龄3.2岁,89.6%入住ICU,均高于其他血清型病例。

核心结论

  • 德国儿童普遍接种PCV13后,血清型3相关肺炎旁胸腔积液/脓胸明显增多,包括较多年幼儿童的血清型3疫苗突破和疫苗失败病例;作者建议未来PCV不仅覆盖新发血清型,还应包含对血清型3更有效的成分。

研究设计与样本

  • 德国全国儿童医院监测研究,纳入2010年10月至2018年6月584例18岁以下细菌学确诊的肺炎旁胸腔积液/脓胸患儿,通过血样本和/或胸腔积液培养和/或PCR鉴定肺炎链球菌并进行血清分型。

主要发现

  • 584例中256例(43.8%)检出肺炎链球菌,其中培养122例、PCR 207例。
  • 114例完成血清分型:血清型3占42.1%,血清型1占25.4%,血清型7F占12.3%,血清型19A占7.9%,其他PCV13血清型占4.4%,非PCV13血清型占7.9%。
  • 2010年10月至2014年6月以血清型1(38.1%)和血清型3(25.4%)最常见;2014年7月至2018年6月以血清型3(62.7%)和非PCV13血清型(15.7%)为主。
  • 与其它肺炎链球菌血清型患儿相比,血清型3相关PPE/PE患儿年龄更小(中位3.2岁[IQR 2.1-4.3岁] vs 中位5.6岁[IQR 3.8-8.2岁];p < 0.001),入住ICU比例更高(43例[89.6%] vs 48例[73.8%];p = 0.04)。
  • 114例肺炎链球菌PPE/PE患儿中76例(66.7%)接种过肺炎链球菌疫苗,其中39例(51.3%)接种的疫苗覆盖所检出血清型;39例中30例按年龄接种PCV13并视为疫苗失败,包括26例血清型3、3例血清型19A和1例血清型1。

临床怎么用

  • 作者建议未来PCV不仅应覆盖新发血清型,还应包含对血清型3更有效的成分。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pediatric pneumococcal pneumonia complicated by parapneumonic pleural effusion/empyema (PPE/PE) remains a major concern despite general immunization with pneumococcal conjugate vaccines (PCVs). METHODS: In a nationwide pediatric hospital surveillance study in Germany we identified 584 children <18 years of age with bacteriologically confirmed PPE/PE from October 2010 to June 2018. Streptococcus pneumoniae was identified by culture and/or PCR of blood samples and/or pleural fluid and serotyped. RESULTS: S. pneumoniae was identified in 256 of 584 (43.8%) children by culture (n = 122) and/or PCR (n = 207). The following pneumococcal serotypes were detected in 114 children: serotype 3 (42.1%), 1 (25.4%), 7F (12.3%), 19A (7.9%), other PCV13 serotypes (4.4%) and non-PCV13 serotypes (7.9%). Between October 2010 and June 2014 serotype 1 (38.1%) and serotype 3 (25.4%) were most prevalent, whereas between July 2014 and June 2018 serotype 3 (62.7%) and non-PCV13 serotypes (15.7%) were dominant. Compared to children with other pneumococcal serotypes, children with serotype 3 associated PPE/PE were younger (median 3.2 years [IQR 2.1-4.3 years] vs. median 5.6 years [IQR 3.8-8.2 years]; p < 0.001) and more frequently admitted to intensive care (43 [89.6%] vs. 48 [73.8%]; p = 0.04). Seventy-six of 114 (66.7%) children with pneumococcal PPE/PE had been vaccinated with pneumococcal vaccines. Thirty-nine of 76 (51.3%) had received a vaccine covering the serotype detected. Thirty of these 39 breakthrough cases were age-appropriately vaccinated with PCV13 and considered vaccine failures, including 26 children with serotype 3, three children with serotype 19A and one child with serotype 1. CONCLUSION: Following the introduction of PCV13 in general childhood vaccination we observed a strong emergence of serotype 3 associated PPE/PE in the German pediatric population, including a considerable number of younger children with serotype 3 vaccine breakthrough cases and failures. Future PCVs should not only cover newly emerging serotypes, but also include a more effective component against serotype 3.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Goettler D, Streng A, Kemmling D, et al. Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany. Vaccine. 2019. PMID: 31735502. doi:10.1016/j.vaccine.2019.10.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。